Clinical Report: Creation and assessment of a nomogram for forecasting symptomatic recurrence post-laparoscopic adenomyomectomy
Overview
This study developed and validated a nomogram to predict symptomatic recurrence after laparoscopic adenomyomectomy in patients with adenomyosis. The nomogram demonstrated an area under the curve (AUC) of 0.776.
Background
Adenomyosis is a prevalent gynecologic condition affecting women of reproductive age. Uterine-sparing surgeries, such as laparoscopic adenomyomectomy, are alternatives for women seeking to preserve fertility, yet they carry a risk of symptomatic recurrence. Accurate prediction of recurrence is essential for guiding postoperative management.
Data Highlights
Predictor
Significance
Previous surgical history of ovarian endometrioma
Independent predictor
Preoperative CA125 level
Independent predictor
Concomitant ovarian endometrioma
Independent predictor
Postoperative medication modality
Independent predictor
Duration of postoperative therapy
Independent predictor
Key Findings
The nomogram was based on a cohort of 484 patients who underwent laparoscopic adenomyomectomy.
Symptomatic recurrence occurred in 131 patients, while 353 remained recurrence-free.
Independent predictors of recurrence included previous surgical history of ovarian endometrioma and preoperative CA125 level.
The nomogram achieved an AUC of 0.776, indicating good discriminatory ability.
Calibration curves demonstrated good performance, and decision curve analysis indicated high net benefit for predicted probabilities between 0% and 60%.
Clinical Implications
The nomogram provides a tool for estimating the risk of symptomatic recurrence in patients post-laparoscopic adenomyomectomy.
Conclusion
The developed nomogram offers a promising approach for predicting symptomatic recurrence after laparoscopic adenomyomectomy, though further multicenter validation is necessary to confirm its clinical utility.
A two-marker methylated DNA assay identified endometrial cancer with 96% sensitivity in self-collected vaginal fluid — but prospective validation is needed before it can reduce biopsies in routine care.